New York is currently home to 4495 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Monetary Incentive Delay Task for Probing Reward-related Neural Processes
NCT06369623
Recruiting
150 males and 150 females ages 14-17 years-old will be enrolled in an observational, longitudinal study. There are three planned in-person visits: a baseline assessment, an 18-month follow-up, and a 36-month follow-up. The in-person visits will include assessment of substance use and other individual differences (e.g., reward function, psychiatric history), neuromelanin-sensitive MRI, as well as functional brain activation collected while the participant is at rest (resting-state fMRI) and while... Read More
Gender:
ALL
Ages:
Between 14 years and 17 years
Trial Updated:
05/12/2025
Locations: Stony Brook Medicine, Stony Brook, New York
Conditions: Adolescent Development
Register for Updates
Long-Term Outcomes of Children With Congenital CMV in New York State
NCT06226558
Recruiting
PROACTIVE NYS is a long-term follow-up study of all infants who test positive for congenital Cytomegalovirus infection (CMV) throughout New York State on the Newborn Screen. By following all infants who screen positive, we will learn important information about the range of symptoms caused by congenital CMV, from those babies with more severe findings to those with no symptoms. In particular, our study will provide new information about many facets of congenital CMV, including: * Developmental... Read More
Gender:
ALL
Ages:
Between 0 days and 1 year
Trial Updated:
05/12/2025
Locations: Stony Brook Children's Hospital, Stony Brook, New York
Conditions: Congenital CMV Infection, Sensorineural Hearing Loss
Register for Updates
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
NCT05963971
Recruiting
The purpose of this study is determine the effectiveness of a six-month virtually-delivered dietary education intervention (PEDALL) on the prevention of overweight and obesity (OW/OB) during maintenance chemotherapy in children and adolescents with acute lymphoblastic leukemia (ALL).
Gender:
ALL
Ages:
Between 5 years and 21 years
Trial Updated:
05/12/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Acute Lymphoblastic Leukemia, Obesity
Register for Updates
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
NCT05952934
Recruiting
This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin. It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year period in terms of reducing cancer recurrence rate by comparing the recurrence rates between the Candin and the placebo arm. The ratio of the number of subjects who will receive Candin versus placebo will be 3:1. Up to 100 subjects will be screened until 80 subjects are eligible for injection.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/12/2025
Locations: Perlmutter Cancer Center at NYU Langone Health, Mineola, New York
Conditions: Squamous Cell Carcinoma of Head and Neck
Register for Updates
Impact of Yo-Yo Sleep on Cardiometabolic Health
NCT05880758
Recruiting
The goal of this clinical trial is to test the impact of repeated intermittent short sleep, with short sleep maintained 5 days per week followed by 2 days of prolonged sleep, compared to daily adequate sleep, on energy balance and cardiometabolic risk. A secondary goal of this research is to determine if maintaining a constant midpoint of sleep while undergoing intermittent short sleep, leads to better outcomes than intermittent short sleep with a 2-hour delay in sleep midpoint. The aims of this... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
05/12/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Cardiometabolic Syndrome, Obesity
Register for Updates
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
NCT05868265
Recruiting
The purpose of this study is to find out whether the study drug, enfortumab vedotin, is an effective and safe treatment for people who have urothelial carcinoma of the upper urinary tract. Study participants will be people who are not eligible to receive or have chosen not to receive the chemotherapy drug cisplatin for treatment of their cancer. In addition, all participants will be planning on having standard surgery to remove their tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities), Commack, New York
Conditions: Urothelial Carcinoma
Register for Updates
Hypoparathyroidism Natural History
NCT05793853
Recruiting
This is a prospective three year natural history study of adults with hypoparathyroidism. The goal is to monitor patients with hypoparathyroidism to define end-organ damage in the context of the disease. Funding Source- FDA OOPD
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/12/2025
Locations: Columbia University Medical Center - Harkness Pavillion, New York, New York
Conditions: Hypoparathyroidism
Register for Updates
Innovations in Genicular Outcomes Registry
NCT05495334
Recruiting
The registry will capture prospective data on patients receiving pain management for chronic pain due to knee osteoarthritis (OA) or pain optimization for knee arthroplasty due to knee OA. The OA pain therapies may include cryo nerve block, radiofrequency ablation (RFA), intra-articular (IA) corticosteroids, viscosupplementation, opioids, and others (e.g., non-steroidal anti-inflammatory drugs \[NSAIDs\]).
Gender:
ALL
Ages:
All
Trial Updated:
05/12/2025
Locations: Genesee Orthopedics and Plastic Surgery (St. Elizabeth Med Center/ Apex Surgical Center), New Hartford, New York
Conditions: Knee Osteoarthritis
Register for Updates
CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2
NCT05467930
Recruiting
The purpose of this study is to describe the long-term health effects of COVID-19 in a population of mostly Black and Latinx individuals and their households who were diagnosed with COVID-19 at Columbia University Irving Medical Center. In New York, the upper Manhattan and south Bronx communities neighboring Columbia University Irving Medical Center (CUIMC) have been two of the most impacted communities of the COVID-19 pandemic. These neighborhoods are predominantly non-Hispanic black or African... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: COVID-19, SARS CoV 2 Infection
Register for Updates
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
NCT05318105
Recruiting
The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop diuretics in patients with worsening heart failure (HF) and fluid overload.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Mount Sinai Morningside, New York, New York
Conditions: Heart Failure (for Example, Fluid Overload), Heart Failure, Fluid Overload
Register for Updates
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
NCT05302271
Recruiting
The purpose of this study is to test the safety and preliminary efficacy of AAVrh.10hFXN to treat the cardiomyopathy associated with Friedreich's ataxia (FA). AAVrh.10hFXN is a serotype rh.10 adeno-associated virus gene transfer vector coding for Frataxin (FXN). The drug is administered intravenously. This is a phase 1, open label, dose escalation study with a total of 25 participants.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
05/12/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Friedreich Ataxia, Cardiomyopathies, Cardiac Hypertrophy, Myocardial Fibrosis
Register for Updates
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a and 2) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
NCT05271318
Recruiting
This is an open-label, phase 1/2, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Northwell Heatlh/Lenox Hill Hospital, New York City, New York
Conditions: Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
Register for Updates